Using stem cells to improve treatment for recurrent ovarian cancer
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer
This study is exploring a new way to treat recurrent ovarian cancer using specially modified stem cells that can help deliver medicine directly to the cancer, aiming to improve outcomes and help patients live longer without needing surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11047564 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for recurrent ovarian cancer by utilizing a specially engineered stem cell platform. The goal is to create a non-surgical method that targets and overcomes drug resistance in patients whose cancer has returned after initial treatment. By genetically modifying adipose-derived stem cells to enhance their ability to deliver therapeutic agents directly to cancer cells, the research aims to improve patient outcomes and extend survival. Patients may benefit from this innovative approach if it successfully reduces metastasis and prevents cancer relapse.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with recurrent ovarian cancer who have developed resistance to standard chemotherapy treatments.
Not a fit: Patients with early-stage ovarian cancer or those who have not yet experienced recurrence may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with recurrent ovarian cancer, potentially improving survival rates.
How similar studies have performed: While the use of stem cells in cancer treatment is an emerging field, this specific approach targeting recurrent ovarian cancer is novel and has not been extensively tested in prior studies.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Hatefi, Arash — Rutgers Biomedical and Health Sciences
- Study coordinator: Hatefi, Arash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.